Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eleven research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $10.25.

BDTX has been the topic of several recent research reports. Weiss Ratings cut shares of Black Diamond Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, July 13th. Raymond James Financial restated an “outperform” rating on shares of Black Diamond Therapeutics in a report on Thursday, August 6th.

TD Cowen restated a “buy” rating on shares of Black Diamond Therapeutics in a report on Thursday, August 6th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Black Diamond Therapeutics in a research report on Thursday, August 6th.

Black Diamond Therapeutics Trading Up 1.1% Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.17)

earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.03. On average, equities research analysts predict that Black Diamond Therapeutics will post -0.57 EPS for the current year. Hedge Funds Weigh In On Black Diamond Therapeutics Large investors have recently bought and sold shares of the business. BlackRock Inc.

bought a new stake in Black Diamond Therapeutics during the 2nd quarter valued at $7,247,000. Renaissance Technologies LLC increased its holdings in shares of Black Diamond Therapeutics by 73.1% in the 1st quarter. Renaissance Technologies LLC now owns 1,643,747 shares of the company’s stock valued at $3,501,000 after acquiring an additional 694,012 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Black Diamond Therapeutics by 51.9% in the 1st quarter.

Dimensional Fund Advisors LP now owns 1,301,664 shares of the company’s stock valued at $2,772,000 after acquiring an additional 444,649 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Black Diamond Therapeutics in the 2nd quarter valued at $2,022,000. Finally, AWM Investment Company Inc. bought a new position in shares of Black Diamond Therapeutics in the 2nd quarter worth $1,850,000.

Institutional investors own 95.47% of the company’s stock. About Black Diamond Therapeutics Black Diamond Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company uses its MasterKey platform to identify cancer-driving mutations and develop small-molecule therapies intended to address mutations across multiple tumor types, rather than focusing exclusively on a single tissue or cancer diagnosis.

Its pipeline has included brain-penetrant targeted therapies designed for patients with oncogenic alterations in pathways such as EGFR and RAF. Featured Stories - Five stocks we like better than Black Diamond Therapeutics - The Grocery Shelf Battle Is Changing—Who Comes Out Ahead? - 3 Unique ETFs With Strong Momentum for the End of the Year - 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead - Schneider Just Paid Up for PTC—Is the SaaSpocalypse Overdone? Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.